Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients

Inclusion Criteria: * Asymptomatic HIV-1-infected individuals who are treatment-experienced and who have not been on ART for at least 16 weeks. * Have documented prior non-suppressive ART including at least 1 NRTI, 1 NNRTI and 2 PIs; or have documented prior ART resistance to at least 1 NRTI, 1 NNRTI and 1 PI; AND in the opinion of the investigator, have few, if any, effective treatment options available. * Have \>2,500 copies/mL of HIV-1 RNA at screening. * Have a stable CD4 cell count while off ART and \>250 cells/mL at screening. * Have no clinically significant findings on screening evaluations. Exclusion Criteria: * Have a current or recent opportunistic infection that, in the opinion of the investigator, is not being controlled by medication. * Have any condition that, in the opinion of the investigator, could compromise subject safety or adherence to the protocol. * Have a documented positive test for hepatitis B surface antigen, or have received any antiviral therapy for hepatitis C \<6 weeks prior to study drug administration.